Allogene Therapeutics will host a conference call on April 13, 2026, to discuss interim results from its ALPHA3 trial.
Quiver AI Summary
Allogene Therapeutics, a biotechnology company based in South San Francisco, announced a conference call and webcast scheduled for April 13, 2026, to discuss the interim futility analysis of its pivotal Phase 2 ALPHA3 trial regarding cemacabtagene ansegedleucel (cema-cel) for treating first-line consolidation large B-cell lymphoma. The event will begin at 5:30 a.m. PT / 8:30 a.m. ET, with a registration link provided for attendees. Allogene focuses on developing allogeneic CAR T cell therapies for cancer and autoimmune diseases, aiming to provide readily available "off-the-shelf" treatment options for patients. Further details can be accessed on their website.
Potential Positives
- Announcement of a conference call and webcast to discuss interim futility analysis indicates transparent communication with investors and stakeholders.
- Progress in the pivotal, randomized Phase 2 ALPHA3 trial for cemacabtagene ansegedleucel (cema-cel), suggesting ongoing development in an important area of cancer treatment.
- Company's focus on allogeneic CAR T products positions it as a leader in the evolving field of cell therapy, which may enhance investor confidence.
Potential Negatives
- The announcement of an interim futility analysis may raise concerns about the efficacy of cemacabtagene ansegedleucel (cema-cel) in the ongoing clinical trial, potentially affecting investor confidence and market perception.
- Hosting a conference call to review an interim futility analysis suggests that the trial's results may not be meeting predetermined success criteria, which could lead to uncertainty about the company's future prospects.
- Widespread uncertainty surrounding the trial outcomes may negatively impact Allogene Therapeutics' stock performance in the short term, as investors may react to potential setbacks in the product's development.
FAQ
What is the ALPHA3 trial studying?
The ALPHA3 trial is investigating the efficacy of cemacabtagene ansegedleucel (cema-cel) in treating first-line consolidation large B-cell lymphoma.
When is the Allogene Therapeutics conference call?
The conference call will be held on April 13, 2026, at 5:30 a.m. PT / 8:30 a.m. ET.
How can I access the conference call and webcast?
You can register for the conference call using the provided link and access the webcast on Allogene's website under the Investors tab.
What is Allogene Therapeutics focusing on?
Allogene Therapeutics specializes in developing allogeneic CAR T products for cancer and autoimmune diseases.
Where can I find more information about Allogene Therapeutics?
More information is available on their official website at www.allogene.com.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$ALLO Insider Trading Activity
$ALLO insiders have traded $ALLO stock on the open market 12 times in the past 6 months. Of those trades, 0 have been purchases and 12 have been sales.
Here’s a breakdown of recent trading of $ALLO stock by insiders over the last 6 months:
- DAVID D CHANG (President and CEO) has made 0 purchases and 2 sales selling 143,032 shares for an estimated $289,458.
- ZACHARY ROBERTS (EVP of R&D) has made 0 purchases and 2 sales selling 61,969 shares for an estimated $104,168.
- GEOFFREY M. PARKER (CHIEF FINANCIAL OFFICER) has made 0 purchases and 2 sales selling 60,745 shares for an estimated $88,410.
- BENJAMIN MACHINAS BENESKI (SVP, Chief Technical Officer) has made 0 purchases and 4 sales selling 20,302 shares for an estimated $44,504.
- EARL MARTIN DOUGLAS (SVP, General Counsel) sold 22,900 shares for an estimated $40,304
- ANNIE YOSHIYAMA (SVP, Finance) sold 4,167 shares for an estimated $7,167
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$ALLO Hedge Fund Activity
We have seen 76 institutional investors add shares of $ALLO stock to their portfolio, and 69 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- CANDRIAM S.C.A. added 2,305,644 shares (+inf%) to their portfolio in Q4 2025, for an estimated $3,158,732
- UBS GROUP AG removed 2,181,564 shares (-61.1%) from their portfolio in Q4 2025, for an estimated $2,988,742
- PATIENT SQUARE CAPITAL LP added 1,982,360 shares (+66.5%) to their portfolio in Q4 2025, for an estimated $2,715,833
- CITADEL ADVISORS LLC removed 1,860,137 shares (-13.3%) from their portfolio in Q4 2025, for an estimated $2,548,387
- MILLENNIUM MANAGEMENT LLC removed 1,548,719 shares (-45.7%) from their portfolio in Q4 2025, for an estimated $2,121,745
- DIMENSIONAL FUND ADVISORS LP removed 1,132,937 shares (-54.2%) from their portfolio in Q4 2025, for an estimated $1,552,123
- PRIMECAP MANAGEMENT CO/CA/ added 1,060,532 shares (+15.0%) to their portfolio in Q4 2025, for an estimated $1,452,928
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$ALLO Price Targets
Multiple analysts have issued price targets for $ALLO recently. We have seen 4 analysts offer price targets for $ALLO in the last 6 months, with a median target of $8.0.
Here are some recent targets:
- John Newman from Canaccord Genuity set a target price of $14.0 on 03/13/2026
- Biren Amin from Piper Sandler set a target price of $8.0 on 03/13/2026
- Reni Benjamin from Citizens set a target price of $5.0 on 01/09/2026
- Michael Yee from UBS set a target price of $8.0 on 01/07/2026
Full Release
SOUTH SAN FRANCISCO, Calif., April 10, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease, today announced the Company will host a conference call and webcast to review the interim futility analysis from its pivotal, randomized Phase 2 ALPHA3 trial with cemacabtagene ansegedleucel (cema-cel) in first-line (1L) consolidation large B-cell lymphoma (LBCL) on Monday, April 13, 2026.
The live conference call and webcast will take place at 5:30 a.m. PT / 8:30 a.m. ET. Please use this link to register. The webcast will be made available on the Company's website at www.allogene.com under the Investors tab in the News and Events section.
About Allogene Therapeutics
Allogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T) products for cancer and autoimmune disease. Led by cell therapy veterans applying proven CAR T experience, Allogene is developing a pipeline of “off-the-shelf” CAR T cell product candidates with the goal of delivering readily available cell therapy on-demand, more reliably, and at greater scale to more patients. For more information, please visit
www.allogene.com
, and follow Allogene Therapeutics on X and LinkedIn.
Allogene Media/Investor Contact:
Christine Cassiano
EVP, Chief Corporate Affairs & Brand Strategy Officer
[email protected]
